128 results
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
20 Mar 24
RepliCel announces a Letter of Intent for Asset Purchase Agreement
4:38pm
of successful safety and dose-finding clinical studies. RCT-01 and RCS-01 are exclusively licensed in Greater China to YOFOTO (China) Health Company
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
or corticosteroids, which are limited in efficacy;
belief that the data from a phase 1/2 clinical trial to test the safety and efficacy of injections … to a phase 2 trial and the design of such a dose-finding trial;
belief that the data from the phase 1 clinical trial to test the safety and certain
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
, which are limited in efficacy;
belief that the data from a phase 1/2 clinical trial to test the safety and efficacy of injections of RCT-01 on patients … and the design of such a dose-finding trial;
belief that the data from the phase 1 clinical trial to test the safety and certain biological outcomes
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
19 Oct 23
Current report (foreign)
1:45pm
has been the subject of successful safety and dose-finding clinical studies and is now the subject of its third clinical study evaluating efficacy
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
4 Oct 23
RepliCel Provides Default Status Update and Announces Shareholder Approval of Equity Incentive Plan
2:23pm
for hair restoration. RCH-01 has been the subject of successful safety and dose-finding clinical studies and is now the subject of its third clinical
6-K
EX-99.1
lxp07 y5edwu
13 Sep 23
RepliCel Announces DermaPrecise™ Development Milestone, Updates Arbitration Proceedings
5:32pm
6-K
EX-99.2
auezovbn4wx6ka
13 Sep 23
RepliCel Announces DermaPrecise™ Development Milestone, Updates Arbitration Proceedings
5:32pm
6-K
EX-99.1
8ktod5
7 Sep 23
Current report (foreign)
12:26pm
6-K
EX-99.1
ruvd zv4mi38g9c6
29 Aug 23
RepliCel announces the passing of long time Chief Financial Officer Simon Ma; David Kwok is appointed Chief Financial Officer
1:14pm
6-K
EX-99.2
e19n buxxfj9lykv489s
17 Aug 23
Annual General and Special Meeting
11:22am
6-K
EX-99.4
rwt8nz8
17 Aug 23
Annual General and Special Meeting
11:22am
6-K
EX-99.2
2k2jad45
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
6-K
EX-99.1
08rrt2
18 May 23
RepliCel Applies to Extend Warrant and Stock Option Expiry Dates and Announces Grant of Stock Options
1:58pm
6-K
EX-99.2
19qn3s8u0q7en
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
6-K
EX-99.5
uk6qcjaw wa
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
6-K
EX-99.2
7hy2ix3l1aau 46j6mp6
25 Oct 22
Current report (foreign)
12:27pm
6-K
EX-99.1
fhyxj3
25 Oct 22
Current report (foreign)
12:27pm
20-F/A
6155beq3x34c5 on6tw
12 Sep 22
Annual report (foreign) (amended)
6:17pm
6-K
EX-99.1
1wtixokio qhvs8xjzy
6 Sep 22
RepliCel Announces Non-brokered Private Placement
2:35pm